Business news from Ukraine

DARNITSA LAUNCHES PRODUCTION OF DRUGS AGAINST RADIATION

Darnitsa pharmaceutical company (Kyiv), within the framework of cooperation with the Ministry of Health of Ukraine and the National Security and Defense Council, has registered and produced the drug Potassium Iodide-125-Darnitsa, designed to protect people from radiation, Dmytro Shymkiv, the chairman of the board of directors of Darnitsa Group, wrote about this on Facebook.
He said that the drug was created in accordance with the regulations for iodine prophylaxis in the event of a radiation accident.
In addition, Shymkiv said that last week Darnitsa donated 525,000 packages (5.25 million tablets) from the first batch of Potassium Iodide-125-Darnitsa to the public health center of the Ministry of Health for free. This will make it possible to carry out iodine prophylaxis if necessary for more than 5 million people.
Potassium iodide is used to protect the thyroid from radiation buildup. The risk of radiation damage to the thyroid gland can be reduced or even leveled with the timely appointment of iodine prophylaxis. The optimal effect of iodine prophylaxis is achieved with preventive intake of potassium iodide for 6 hours or less, as well as simultaneously with the intake of radioactive isotopes of iodine or entering the contaminated zone.

, , ,

E-PRESCRIPTION FOR ALL PRESCRIPTION DRUGS TO START WORKING IN MARCH 2022

Ukraine will launch an electronic prescription for all prescription drugs in March 2022, Head of the Parliament Committee on Public Health, Medical Assistance and Medical Insurance MP Mykhailo Radutsky (Servant of the People faction) said.
“Three weeks ago, at a meeting of the committee, I initiated consideration of the issue of introducing an e-prescription. We agreed with the leadership of the Ministry of Health, the National Health Service and the State Expert Center on a clear timetable for the implementation of the project. In general terms, the plan is as follows: in September of this year, a tender is planned for the development of software for the e-prescription introduction in the electronic health care system. In early 2022, the Ministry of Health will conduct training for doctors and pharmacists on how to use the system. The E-prescription for insulin drugs will start working in October, for all prescription drugs – in March 2022,” he wrote on Facebook.
As Radutsky said, with the introduction of the e-prescription, the uncontrolled sale of drugs, in particular antibiotics, will stop, and control over the prescription of drugs will appear.
“Already in 2021, the patient’s electronic medical record should start working. All information about the patient, the treatment plan, prescribed medications will be collected there. With the advent of the e-prescription, the doctor will be forced to prescribe drugs not at his own discretion, but according to the treatment plan – in accordance with the approved protocols. Accordingly, it will be possible to control the correctness of the actions of a medical worker,” he said.

, ,

RETAIL SALES OF DRUGS IN UKRAINE FALL BY 16.5% IN HRYVNIA EQUIVALENT – STATISTICS

Retail sales of medicines in January 2021 in monetary terms decreased 16.5% compared to January 2020, to UAH 3.117 billion, in packages they decreased by 34.2%, to 36 million units.
At the same time, according to the data provided in the SMD report, domestic manufacturers accounted for 69% of the market in volume terms, while in monetary terms, their share accounted for 35% of the market.
In packages, the top three market leaders included Darnitsa, Farmak and Kyiv Vitamin Plant.
In monetary terms, the top three dealers included Farmak, Sanofi and Darnitsa.

,

NECESSARY TO USE TECHNOLOGY TRANSFER TO EXPAND PRESENCE OF INNOVATIVE DRUGS IN UKRAINE – PETRO BAHRIY

In order to expand the presence of innovative drugs in Ukraine, it is necessary to use the technology transfer mechanism, President of the Association of Manufacturers of Medications of Ukraine (AMMU) Petro Bahriy believes.
“The localization of production makes it possible to bring such products to the Ukrainian market. Roche had localized drugs protected by a patent. There is another example, when JSC Farmak, thanks to a technology transfer, began production of insulin for Eli Lilly. It was an innovative medicine. The project is still being developed at Farmak and is considered very successful. They sell insulin in other markets and the country only benefits from this,” he said in an exclusive interview with Interfax-Ukraine.
At the same time, Bahriy stressed that for the implementation of technology transfer projects, a “message” is needed from the state that it is ready to buy effective innovative drugs.
“In order for original innovative Ukrainian products to appear, we need to invest in science and development, and this is very expensive. Technology transfer is the best mechanism, but cooperation with transnational corporations is impossible in a situation where the state declares that we buy the cheapest,” he said.

,